INHIBITION OF HIV INFECTION THROUGH CHEMOPROPHYLAXIS
First Claim
1. A process of protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus comprising:
- (a) selecting a primate host not infected with the immunodeficiency retrovirus, and(b) administering directly to an uninfected primate host a combination comprising;
i. a pharmaceutically effective amount of emtricitabine; and
ii. a pharmaceutically effective amount of tenofovir or a tenofovir prodrug,wherein the combination is administered orally prior to the exposure of the primate host to the immunodeficiency retrovirus,thereby protecting the primate host from infection with the immunodeficiency retrovirus.
1 Assignment
0 Petitions
Accused Products
Abstract
A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.
1 Citation
19 Claims
-
1. A process of protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus comprising:
-
(a) selecting a primate host not infected with the immunodeficiency retrovirus, and (b) administering directly to an uninfected primate host a combination comprising; i. a pharmaceutically effective amount of emtricitabine; and ii. a pharmaceutically effective amount of tenofovir or a tenofovir prodrug, wherein the combination is administered orally prior to the exposure of the primate host to the immunodeficiency retrovirus, thereby protecting the primate host from infection with the immunodeficiency retrovirus. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 19)
-
-
12. A process for inhibiting establishment of a human immunodeficiency virus self-replicating infection of human immunodeficiency virus infection in a human, comprising:
-
(a) selecting an uninfected human that does not have the self-replicating infection; and (b) administering to the uninfected human a combination comprising; i. a pharmaceutically effective amount of emtricitabine; and ii. a pharmaceutically effective amount of tenofovir or a tenofovir prodrug; thereby inhibiting the establishment of the self-replicating infection with the immunodeficiency virus in the human. - View Dependent Claims (13, 14, 15, 16, 17, 18)
-
Specification